(12) Patent Application Publication (10) Pub. No.: US 2010/0135901 A1 Moller Et Al

Total Page:16

File Type:pdf, Size:1020Kb

(12) Patent Application Publication (10) Pub. No.: US 2010/0135901 A1 Moller Et Al US 20100135901A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0135901 A1 Moller et al. (43) Pub. Date: Jun. 3, 2010 (54) COMBINATION THERAPY now abandoned, which is a continuation of application No. PCT/DK2004/000683, filed on Oct. 8, 2004. (76) Inventors: Niels Peter Hundahl Moller, (60) Provisional application No. 60/513,422, filed on Oct. Kobenhavn O (DK); Kresten Skak, 22, 2003, provisional application No. 60/569,566, Soborg (DK); Jorn Roland Miller, filed on May 10, 2004. Virum (DK) (30) Foreign Application Priority Data Correspondence Address: WOODCOCKWASHIBURN LLP Oct. 17, 2003 (DK) ............................. PA2OO3O1529 CIRA CENTRE, 12TH FLOOR, 2929 ARCH May 4, 2004 (DK) ............................. PA2004OO707 STREET PHILADELPHIA, PA 19104-2891 (US) Publication Classification (51) Int. Cl. (21) Appl. No.: 12/637,109 A6II 5L/00 (2006.01) A638/20 (2006.01) (22) Filed: Dec. 14, 2009 A6IP35/00 (2006.01) (52) U.S. Cl. ....................................... 424/1.11; 424/85.2 Related U.S. Application Data (57) ABSTRACT (63) Continuation of application No. 12/112,452, filed on Apr. 30, 2008, now abandoned, which is a continuation The invention provides combination treatments with IL-21, of application No. 1 1/404,733, filed on Apr. 14, 2006, analogues and derivatives thereof. US 2010/0135901 A1 Jun. 3, 2010 COMBINATION THERAPY cells have been shown to kill some types of tumor cells via KIR ligand dependent activation. CROSS-REFERENCE TO RELATED PATENT 0007. The immunology involved in cancer disease APPLICATIONS includes a variety of different cells derived from the immune system. Compounds which stimulate Such responses may be 0001. This patent application is a continuation of U.S. used in combination to provide an improved response to patent application Ser. No. 12/112,452 filed on Apr. 30, 2008, tumor treatment. which is a continuation of U.S. patent application Ser. No. 0008 Interleukin 21 (IL-21) has been shown to affect a 1 1/404.733, filed on Apr. 14, 2006, now abandoned, which is number of different cells of the immune system. Of particular a continuation of International Patent Application PCT/ interest is the observed activation of cytotoxic T lymphocytes DK2004/000683 (published as WO 2005/037306), filed Oct. (CTLs) and NK cells. Both cell types are known to be criti 8, 2004 (and designating the US) and claims the benefit cally involved in combating tumors. Thus, the presence of (under 35 USC S119) of U.S. Provisional Patent Application intratumoral T lymphocytes is correlated with improved Nos. 60/513,422 and 60/569,566, filed Oct. 22, 2003 and May clinical outcome for a number of different cancers (Zhang et 10, 2004, respectively, as well as Danish Patent Application al. 2003). However, tumor infiltrating lymphocytes (TILs) are Nos. PA 2003 01529 and PA 2004 00707, filed October 17, not always sufficiently activated to control tumor growth 2003 and May 4, 2004, respectively, the entirety of each of (Dunn et al. 2002: Kataki et al. 2002: Blohm et al. 2002: which is hereby incorporated by reference. Khong and Restifo 2002). Therefore, there is a need for improved therapeutic regimens for treatment, management FIELD OF THE INVENTION and prevention of cancers. Another important aspect of 0002 The present invention relates to IL-21, analogues or IL-21's effect on the immune system is the effect on B cells, derivatives and their use in combination with other pharma which can lead to an improved antibody response against ceutical compounds in treatment of cancer and viral infec tumor cells and virus-infected cells. The present invention tions. relates to combined use of IL-21 and other modalities for treatment and management of cancer and viral infections. BACKGROUND OF THE INVENTION 0009. Although synthetic therapeutic vaccines consisting 0003 Cytokines generally stimulate proliferation or dif of one or only few defined antigens have shown some utility ferentiation of cells of the hematopoietic lineage or partici in cancer treatment there is a strong need for improvement. pate in the immune and inflammatory response mechanisms The present invention also relates to a timely combination of of the body. The interleukins are a family of cytokines that (i) release of tumor antigens leading to an immune response mediate immunological responses by producing many cytok directed towards these tumor antigens and (ii) the unique ines and effect adaptive immunity to antigens. Mature T cells ability of IL-21 to induce a sustained cytotoxic T cell (CTL) can be activated, i.e., by an antigen or other stimulus, to response. The release of tumor antigens can be obtained with produce, for example, cytokines, biochemical signaling mol a number of different approaches including the following ecules, or receptors that further influence the fate of the T cell non-limiting examples: (i) conventional chemotherapy, (ii) population. induction of apoptosis, (ii) induction of tumor cell death via 0004 Cytokines produced by the T cell have been classi interference with the blood supply to the tumor, (iv) interfer fied as type 1 and type 2 (Kelso, A. Immun. Cell Biol. 76:300 ence with growth factor stimulation and signal transduction. 317, 1998). Type 1 cytokines include interleukin 2 (IL-2), IFN-Y, LTO, and are involved in inflammatory responses, SUMMARY OF THE INVENTION viral immunity, intracellular parasite immunity and allograft 0010. In one aspect, the present invention provides com rejection. Type 2 cytokines include IL-4, IL-5, IL-6, IL-10 positions comprising a combination of a first component and IL-13, and are involved in humoral responses, helminth selected from the group consisting of (a) human IL-21, (b) an immunity and allergic response. Shared cytokines between analogue of IL-21, and (c) a derivative of IL-21; and a second Type 1 and 2 include IL-3, GM-CSF and TNF-C. There is component comprising a radio-pharmaceutical selected from Some evidence to suggest that Type 1 and Type 2 producing T the group consisting of Cesium-137, Iridium-192, Ameri cell populations preferentially migrate into different types of cium-241, Gold-198, Cobalt-57, Copper-67, Technetium-99, inflamed tissue. Iodide-123, Iodid-131 and Indium-111. Another aspect of Mature T cells can be activated, i.e., by an antigen or other invention provides compositions comprising a combination stimulus, to produce, for example, cytokines, biochemical of a first component selected from the group consisting of (a) signaling molecules, or receptors that further influence the human IL-21, (b) an analogue of IL-21, and (c) a derivative of fate of the T cell population. IL-21; and a second component comprising a cell-cycle regu 0005 B cells can be activated via receptors on their cell lator or apoptosis-inducing agent, wherein the second com Surface including B cell receptor and other accessory mol ponent is selected from the group consisting of cdc-25, NSC ecules to perform accessory cell functions, such as production 66384, flavopiridol, 7-hyroxystaurosporine, roscovitine, and of cytokines and antibodies. BIBR1532 XOTO95. 0006 Natural killer (NK) cells have a common progenitor 0011 Further aspects include compositions comprising a cell with T cells and B cells, and play a role in immune combination of a first component selected from the group surveillance. NK cells, which comprise up to 15% of blood consisting of (a) human IL-21, (b) an analogue of IL-21, and lymphocytes, do not express antigen receptors, and therefore (c) a derivative of IL-21; and a second component comprising do not use MHC recognition as requirement for binding to a an anti-angiogenesis drug selected from the group consisting target cell. NK cells are involved in the recognition and killing of avastin, neovastat, thalidomide, PTK787, ZK222584, of certain tumor cells and virally infected cells. In vivo, NK ZD-6474, SU6668, PD547,632 VEGF-Trap, CEP-7055, cells are believed to require activation, however, in vitro, NK NM-3, and SU 11248. US 2010/0135901 A1 Jun. 3, 2010 0012. In another aspect, the present invention provides kaemia (other), liver, liver (secondary), lung, lung (second compositions comprising a combination of a first component ary), lymph nodes (secondary), lymphoma (hodgkin's), lym selected from the group consisting of (a) human IL-21, (b) an phoma (non-hodgkin’s), melanoma, mesothelioma, analogue of IL-21, and (c) a derivative of IL-21; a second myeloma, ovary, pancreas, penis, prostate, skin, soft tissue component comprising IFN-O, and a third component com sarcomas, Stomach, testes, thyroid, unknown primary tumor, prising thymopentin. vagina, Vulva, womb (uterus). 0013 Another aspect provides compositions comprising a 0020 Soft tissue tumors include Benign schwannoma combination of a first component selected from the group Monosomy, Desmoid tumor, Lipo-blastoma, Lipoma, Uter consisting of (a) human IL-21, (b) an analogue of IL-21, and ine leiomyoma, Clear cell sarcoma, Dermatofibrosarcoma, (c) a derivative of IL-21; a second component comprising Ewing sarcoma, Extraskeletal myxoid chondrosarcoma, cis-platin ; and a third component comprising IFN-C. Also, Liposarcoma myxoid, Liposarcoma, well differentiated, embodied are compositions that further comprise atamoxifen Alveolar rhabdomyosarcoma, and Synovial sarcoma. component or a Carmustine component. Variations of the 0021 Specific bone tumor include Nonossifying Fibroma, compositions can include further additions to the composi Unicameral bone cyst, Enchon-droma, Aneurysmal bone tion of decarbazine
Recommended publications
  • Thymic Peptides and Preparations: an Update
    ¡ Archivum Immunologiae et Therapiae Experimentalis, 1999, 47¢ , 77–82 £ PL ISSN 0004-069X Review Thymic Peptides and Preparations: an Update ¤ O. J. Cordero et al.: Thymic Peptides ¦ ¨ § OSCAR J. CORDERO, A¥ LICIA PIÑEIRO and MONTSERRAT NOGUEIRA Department of Biochemistry and Molecular Biology, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain Abstract. The possibilities of thymic peptides in human therapy are still being described. Here, we focus on their © general characteristics and on recent advances in this area. Key words: thymus; thymic peptides; preclinical investigation; therapeutic use; clinical trials. Thymic peptides, as well as a variety of other purified from porcine and human serum and from calf modulators (IL-1, IL-3, IL-6, GM-CSF) and cell-cell thymus, and named “facteur thymique serique”11. interactions, regulate the process known as thymic se- According to the classical criteria, TH is the unique lection by which pro-thymocytes become mature and peptide that can be recognized as a hormone. Its secre- functional T cells. tion by a subpopulation of thymic epithelial cells (TEC) Several polypeptides have been extracted, mainly is controlled by a pleiotropic mechanism involving its from young calves, and some of them have been suc- own levels and those of prolactine (PRL), growth hor- cessfully isolated and prepared synthetically (Fig. 1). mone (GH) through insulin growth factor 1 (IGF-1) se- The precise role of much of these factors purported to cretion, adrenocorticotropin (ACTH), thyroxin (T4), β- have intrathymic effects is still unknown, although endorphin and β-leukencephalin and IL-1α and β8. many of these compounds exhibit immunobiological Furthermore, reciprocal regulatory actions on the activity.
    [Show full text]
  • Thymopentin and Splenopentin As Immunomodulators Current Stutus
    Immunologic Research 1998;17/3:345-368 Thymopentin and Splenopentin as Immunomodulators Current Stutus 1Department of Immunology, Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Lucknow, India. 2Division of Biopolymers, Central Drug Research Institute, Lucknow, India. 3Department of Microbiology, RML Awadh University, Faizabad, India. Abstract Key Words Splenopentin (SP-5, Arg-Lys-Glu-Val-Tyr) and thymopentin (TP-5, Immunomodulation Arg-Lys-Asp-Val-Tyr) are synthetic immunomodulating peptides Splenin corresponding to the region 32-34 of a splenic product called splenin Splenopentin (SP) and the thymic hormone thymopoietin (TP), respectively. TP Thymopoietin was originally isolated as a 5-kDa (49-amino acids) protein from Thymopentin bovine thymus while studying effects of the thymic extracts on neuro- muscular transmission and was subsequently observed to affect T cell differentiation and function. TP I and II are two closely related polypeptides isolated from bovine thymus. A radioimmunoassay for TP revealed a crossreaction with a product found in spleen and lymph node. This product, named splenin, differs from TP only in position 34, aspartic acid for bovine TP and glutamic acid for bovine splenin and it was called TP III as well. Synthetic pentapeptides (TP-5) and (SP-5), reproduce the biological activities of TP and SP, respectively. It is now evident that various forms of TPs were created by proteolytic cleavage of larger proteins during isolation, cDNA clones have been isolated for three alternatively spliced mRNAs that encodes three distinct human T cell TPs. The immunomodulatory properties of TP, SP, TP-5, SP-5 and some of their synthetic analogs reported in the literature have been briefly reviewed.
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Nucleophilic Rhodanine, Thiazolidine-2,4-Dione and Thiazol-4(5H)-One Substrates in Asymmetric Reactions
    The Free Internet Journal Review for Organic Chemistry Archive for Organic Chemistry Arkivoc 2019, part i, 256-292 Nucleophilic rhodanine, thiazolidine-2,4-dione and thiazol-4(5H)-one substrates in asymmetric reactions Sushovan Paladhi,*a Barnali Jana,*b Sudipta Pathak,b and Saikat Kumar Mannab a Department of Chemistry, Anugrah Narayan Singh College, Barh, Patna, Bihar, 803 213, India b Department of Chemistry, Haldia Govt. College, Haldia, Purba Medinipur, West Bengal, 721 657, India Email: [email protected] [email protected] Dedicated to Professor Choong Eui Song on the occasion of his 65th birthday Received 02-12-2019 Accepted 05-05-2019 Published on line 06-16-2019 Abstract Substituted rhodanines, thiazolidine-2,4-diones and thiazol-4(5H)-ones as nucleophilic substrates have attracted great attention in asymmetric reactions in the past six years due to their high impact in medicinal and pharmaceutical importance. The current review provides a cursory overview of the synthetic methods developed to access the rhodanine, thiazolidine-2,4-dione and thiazol-4(5H)-one substrates and a summary of their applications in catalytic asymmetric reactions to synthesize a broad range of differently substituted chiral derivatives of the corresponding substrates with tertiary/quaternary stereogenic centres. Keywords: Rhodanines, thiazolidine-2,4-diones; thiazol-4(5H)-ones, asymmetric catalysis, metal catalysis, organocatalysis DOI: https://doi.org/10.24820/ark.5550190.p010.911 Page 256 ©ARKAT USA, Inc Arkivoc 2019, i, 256-292 Paladhi, S. et al. Table of Contents 1. Introduction 2. Synthesis of the Nucleophiles 2.1 Synthesis of N-substituted rhodanines 1 2.2 Synthesis of 5-alkylidene thiazolidine-2,4-diones 2 2.3 Synthesis of 5-alkylidenerhodanines 3 2.4 Synthesis of 5-substituted rhodanines 4 2.5 Synthesis of thiazol-4(5H)-ones 5 3.
    [Show full text]
  • Pulmonary Delivery of Biological Drugs
    pharmaceutics Review Pulmonary Delivery of Biological Drugs Wanling Liang 1,*, Harry W. Pan 1 , Driton Vllasaliu 2 and Jenny K. W. Lam 1 1 Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong, China; [email protected] (H.W.P.); [email protected] (J.K.W.L.) 2 School of Cancer and Pharmaceutical Sciences, King’s College London, 150 Stamford Street, London SE1 9NH, UK; [email protected] * Correspondence: [email protected]; Tel.: +852-3917-9024 Received: 15 September 2020; Accepted: 20 October 2020; Published: 26 October 2020 Abstract: In the last decade, biological drugs have rapidly proliferated and have now become an important therapeutic modality. This is because of their high potency, high specificity and desirable safety profile. The majority of biological drugs are peptide- and protein-based therapeutics with poor oral bioavailability. They are normally administered by parenteral injection (with a very few exceptions). Pulmonary delivery is an attractive non-invasive alternative route of administration for local and systemic delivery of biologics with immense potential to treat various diseases, including diabetes, cystic fibrosis, respiratory viral infection and asthma, etc. The massive surface area and extensive vascularisation in the lungs enable rapid absorption and fast onset of action. Despite the benefits of pulmonary delivery, development of inhalable biological drug is a challenging task. There are various anatomical, physiological and immunological barriers that affect the therapeutic efficacy of inhaled formulations. This review assesses the characteristics of biological drugs and the barriers to pulmonary drug delivery.
    [Show full text]
  • Thymopentin Ameliorates Dextran Sulfate Sodium-Induced Colitis by Triggering
    1 Thymopentin ameliorates dextran sulfate sodium-induced colitis by triggering 2 the production of IL-22 in both innate and adaptive lymphocytes 3 Qiuhua Cao1, 2*, Xinghua Gao1, 2*, Yanting Lin1, 2, Chongxiu Yue1, 2, Yue Wang1, 2, Fei 4 Quan1, 2, Zixuan Zhang1, 2, Xiaoxuan Liu1, 2, Yuan Lu1, 2, Yanling Zhan1, 2, Hongbao 5 Yang1, 2, Xianjing Li1, 2, Di Qin5, Lutz Birnbaumer4, Kun Hao3 & Yong Yang1, 2 6 7 1. State Key Laboratory of Natural Medicines, China Pharmaceutical University, 8 Nanjing, Jiangsu 211198, PR China 9 2. Center for New Drug Safety Evaluation and Research, China Pharmaceutical 10 University, Nanjing, Jiangsu 211198, PR China 11 3. Key Lab of Drug Metabolism & Pharmacokinetics, China Pharmaceutical 12 University, Nanjing, Jiangsu 210009, PR China 13 4. Neurobiology Laboratory, National Institute of Environmental Health Sciences, 14 Research Triangle Park, North Carolina 27709, USA, and Institute of Biomedical 15 Research (BIOMED), Catholic University of Argentina, Buenos Aires C1107AFF, 16 Argentina 17 5. School of Sports and Health, Nanjing sport institute, Nanjing, Jiangsu 210001, PR 18 China 19 *These authors contributed equally to this work. 20 Corresponding author: Yong Yang and Kun Hao, China Pharmaceutical University, 21 Nanjing, China. Phone and Fax: 86-025-86185622. E-mail: [email protected] or 22 [email protected]. 1 23 Abstract 24 Background: Ulcerative colitis (UC) is a chronic inflammatory gastrointestinal disease, 25 notoriously challenging to treat. Previous studies have found a positive correlation 26 between thymic atrophy and colitis severity. It was, therefore, worthwhile to investigate 27 the effect of thymopentin (TP5), a synthetic pentapeptide corresponding to the active 28 domain of the thymopoietin, on colitis.
    [Show full text]
  • Aspects of the Usage of Antineoplastic and 1Mmunomodulating Agents in a Section of the Private Health Care Sector
    ASPECTS OF THE USAGE OF ANTINEOPLASTIC AND 1MMUNOMODULATING AGENTS IN A SECTION OF THE PRIVATE HEALTH CARE SECTOR Wilmarie Rheeders B. Pharm Dissertation submitted in Pharmacy Practice, School of Pharmacy at the Faculty of Health Sciences of the North-West University, Potchefstroom, in partial fulfilment of the requirements for the degree Magister Pharmaciae. Supervisor: Prof M.S. Lubbe Co-supervisor: Dr. J.L. Duminy Co-supervisor: Prof. M.P. Stander Potchefstroom November 2008 For all things are from Him, by Him, and for Him. Glory belongs to Him forever! Amen. (Rom. 11:36) ACKNOWLEDGEMENTS To my Lord and Father whom I love, all the Glory! He gave me the strength, insight and endurance to finish this study. 1 also want to express my sincere appreciation to the following people that have contributed to this dissertation: • To Professor M.S. Lubbe, in her capacity as supervisor of this dissertation, my appreciation for her expert supervision, advice and time she invested in this study. • To Dr. J.L Duminy, oncologist and co-supervisor, for all the useful advice, assistance and time he put aside in the interest of this dissertation. • To Professor M.P. Stander, in his capacity as co-supervisor of this study. • To Professor J.H.P. Serfontein, for his guidance, time, effort and advice. • To the Department of Pharmacy Practice as well as the NRF for the technical and financial support. • To Anne-Marie, thank you for your patience, time and continuous effort you put into the data. • To the Pharmacy Benefit Management company for providing the data for this dissertation.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • Synthesis and Antimicrobial Activity of a New Series of Thiazolidine-2,4-Diones Carboxamide and Amino Acid Derivatives
    molecules Article Synthesis and Antimicrobial Activity of a New Series of Thiazolidine-2,4-diones Carboxamide and Amino Acid Derivatives Rakia Abd Alhameed 1, Zainab Almarhoon 1 , Sarah I. Bukhari 2, Ayman El-Faham 1,3,* , Beatriz G. de la Torre 4,5 and Fernando Albericio 1,5,6,* 1 Department of Chemistry, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia; [email protected] (R.A.A.); [email protected] (Z.A.) 2 Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 4584, Riyadh 11451, Saudi Arabia; [email protected] 3 Chemistry Department, Faculty of Science, Alexandria University, P.O. Box 426, Ibrahimia, Alexandria 12321, Egypt 4 KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4041, South Africa; [email protected] 5 Peptide Science Laboratory, School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa 6 CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, and Department of Organic Chemistry, University of Barcelona, Martí i Franqués 1-11, 08028 Barcelona, Spain * Correspondence: [email protected] or [email protected] (A.E.-F.); [email protected] or [email protected] (F.A.); Tel.: +966-114-673-195 (A.E.-F.); +27-614-009-144 (F.A.) Received: 5 December 2019; Accepted: 25 December 2019; Published: 27 December 2019 Abstract: Novel thiazolidine-2,4-dione carboxamide and amino acid derivatives were synthesized in excellent yield using OxymaPure/N,N0-diisopropylcarbodimide coupling methodology and were characterized by chromatographic and spectrometric methods, and elemental analysis.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs
    Specific Drugs Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs Chief Editors: Ana Dioun Broyles, MD, Aleena Banerji, MD, and Mariana Castells, MD, PhD Ana Dioun Broyles, MDa, Aleena Banerji, MDb, Sara Barmettler, MDc, Catherine M. Biggs, MDd, Kimberly Blumenthal, MDe, Patrick J. Brennan, MD, PhDf, Rebecca G. Breslow, MDg, Knut Brockow, MDh, Kathleen M. Buchheit, MDi, Katherine N. Cahill, MDj, Josefina Cernadas, MD, iPhDk, Anca Mirela Chiriac, MDl, Elena Crestani, MD, MSm, Pascal Demoly, MD, PhDn, Pascale Dewachter, MD, PhDo, Meredith Dilley, MDp, Jocelyn R. Farmer, MD, PhDq, Dinah Foer, MDr, Ari J. Fried, MDs, Sarah L. Garon, MDt, Matthew P. Giannetti, MDu, David L. Hepner, MD, MPHv, David I. Hong, MDw, Joyce T. Hsu, MDx, Parul H. Kothari, MDy, Timothy Kyin, MDz, Timothy Lax, MDaa, Min Jung Lee, MDbb, Kathleen Lee-Sarwar, MD, MScc, Anne Liu, MDdd, Stephanie Logsdon, MDee, Margee Louisias, MD, MPHff, Andrew MacGinnitie, MD, PhDgg, Michelle Maciag, MDhh, Samantha Minnicozzi, MDii, Allison E. Norton, MDjj, Iris M. Otani, MDkk, Miguel Park, MDll, Sarita Patil, MDmm, Elizabeth J. Phillips, MDnn, Matthieu Picard, MDoo, Craig D. Platt, MD, PhDpp, Rima Rachid, MDqq, Tito Rodriguez, MDrr, Antonino Romano, MDss, Cosby A. Stone, Jr., MD, MPHtt, Maria Jose Torres, MD, PhDuu, Miriam Verdú,MDvv, Alberta L. Wang, MDww, Paige Wickner, MDxx, Anna R. Wolfson, MDyy, Johnson T. Wong, MDzz, Christina Yee, MD, PhDaaa, Joseph Zhou, MD, PhDbbb, and Mariana Castells, MD, PhDccc Boston, Mass; Vancouver and Montreal,
    [Show full text]